271
Views
17
CrossRef citations to date
0
Altmetric
Research Papers

Experiences and needs for work participation in employees with rheumatoid arthritis treated with anti-tumour necrosis factor therapy

, , , , , & show all
Pages 2587-2595 | Accepted 01 Apr 2011, Published online: 15 Jun 2011

References

  • Bombardier C, Ware J, Russell IJ, Larson M, Chalmers A, Read JL. Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial. Am J Med 1986;81:565–578.
  • Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial. Arthritis Rheum 1995;38:1568–1580.
  • Doeglas D, Suurmeijer T, Krol B, Sanderman R, Van Leeuwen M, Van Rijswijk M. Work disability in early rheumatoid arthritis. Ann Rheum Dis 1995;54:455–460.
  • Backman CL. Employment and work disability in rheumatoid arthritis. Curr Opin Rheumatol 2004;16:148–152.
  • Lacaille D, Hogg RS. The effect of arthritis on working life expectancy. J Rheumatol 2001;28:2315–2319.
  • Chorus AM, Miedema HS, Wevers CJ, Van der Linden S. Labour force participation among patients with rheumatoid arthritis. Ann Rheum Dis 2000;59:549–554.
  • Breedveld FC, Weisman, MH, Kavanaugh AF, Cohen SB, Pavelka K, Van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GTThe PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
  • Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400–1411.
  • Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35–45.
  • Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66 (Suppl 3):iii2–22.
  • Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009;11 (Suppl 1):S1.
  • Hoving JL, Bartelds GM, Sluiter JK, Sadiraj K, Groot I, Lems WF, Dijkmans BA, Wijbrandts CA, Tak PP, Nurmohamed MT, Voskuyl AE, Frings-Dresen MH. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scand J Rheumatol 2009;38:246–250.
  • Marshall NJ, Wilson G, Lapworth K, Kay LJ. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. Rheumatology (Oxford) 2004;43:1034–1038.
  • Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, Van Vollenhoven RF. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis 2010;69:126–131.
  • Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. Ann Rheum Dis 2009;68:930–937.
  • Allaire S, Wolfe F, Niu J, Zhang Y, Zhang B, Lavalley M. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum 2008;59:1082–1089.
  • Lacaille D, White MA, Backman CL, Gignac MA. Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients' perspective. Arthritis Rheum 2007;57:1269–1279.
  • Mancuso CA, Paget SA, Charlson ME. Adaptations made by rheumatoid arthritis patients to continue working: a pilot study of workplace challenges and successful adaptations. Arthritis Care Res 2000;13:89–99.
  • Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, Kirwan J. Rheumatology outcomes: the patient's perspective. J Rheumatol 2003;30:880–883.
  • Varekamp I, Haafkens JA, Detaille SI, Tak PP, Van Dijk FJ. Preventing work disability among employees with rheumatoid arthritis: what medical professionals can learn from the patients' perspective. Arthritis Rheum 2005;53: 965–972.
  • Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 2007;19:349–357.
  • Herenius MM, Hoving JL, Sluiter JK, Raterman HG, Lems WF, Dijkmans BA, Tak PP, Nurmohamed MT, Voskuyl AE, Frings-Dresen MH. Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab. J Occup Environ Med 2010;52:618–621.
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang SR, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–324.
  • Prevoo ML, Van 't Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte LB, Van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–48.
  • Boeije, H. Analysing in qualitative research: thinking and doing. [[Analyseren in kwalitatief onderzoek: Denken en doen]]. Den Haag, The NetherlandsBoom onderwijs2006.
  • World Health Organisation. International classification of functioning, disability and health (ICF). Geneva: WHO2001.
  • Detaille SI, Haafkens JA, Van Dijk FJ. What employees with rheumatoid arthritis, diabetes mellitus and hearing loss need to cope at work. Scand J Work Environ Health 2003;29:134–142.
  • Nilsson I, Fitinghoff H, Lilja M. Continuing to work after the onset of rheumatoid arthritis. Work 2007;28:335–342.
  • Gilworth G, Woodhouse A, Tennant A, Chamberlain MA. The impact of rheumatoid arthritis in the workplace. Br J Ther Rehabil 2001;8:342–347.
  • Varekamp I, van Dijk FJ. Workplace problems and solutions for employees with chronic diseases. Occup Med (Lond) 2010;60:287–293.
  • Varekamp I, Heutink A, Landman S, Koning CE, de Vries G, van Dijk FJ. Facilitating empowerment in employees with chronic disease: qualitative analysis of the process of change. J Occup Rehabil 2009;19:398–408.
  • Varekamp I, Krol B, van Dijk FJ. Empowering employees with chronic diseases: process evaluation of an intervention aimed at job retention. Int Arch Occup Environ Health 2011;84:35–43.
  • Lacaille D, White MA, Rogers PA, Backman CL, Gignac MA, Esdaile JM. A proof-of-concept study of the ‘Employment and Arthritis: Making It Work’ program. Arthritis Rheum 2008;59:1647–1655.
  • Hoving JL, van der Meer M, Volkova AY, Frings-Dresen MH. Illness perceptions and work participation: a systematic review. Int Arch Occup Environ Health 2010;83:595–605.
  • Haugli L, Strand E, Finset A. How do patients with rheumatic disease experience their relationship with their doctors? A qualitative study of experiences of stress and support in the doctor-patient relationship. Patient Educ Couns 2004;169–174.
  • Pryce J, Munir F, Haslam C. Cancer survivorship and work: symptoms, supervisor response, co-worker disclosure and work adjustment. J Occup Rehabil 2007;17:83–92.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.